INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most common endocrinological disorders in women in reproductive age group with estimated incidence of 5-10 % . 1 It is defined as a heterogenous syndrome complex characterized by the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo/anovulation and/or polycystic ovaries), with the exclusion of related disorders. This is with the recognition that forms of PCOS may occur without overt evidence of hyperandrogenism. 2 In spite of tremendous scientific interest and research, controversy continues regarding almost all aspects of PCOS. Diagnosis, prevalence, etiology, pathophysiology, management, long-term risks, clinical and biochemical features of these women may vary according to race, ethnicity, and criteria used for diagnosis. Hyperinsulinemia and Insulin Resistance (IR) has proved to be a key link in the generation of the symptoms of Department of Obstetrics & Gynaecology, Acharya Vinoba Bhave Rural Hospital (AVBRH), DMIMS (DU), Sawangi (Meghe), Wardha, Maharashtra, India Given the association between PCOS and IR, insulinsensitizing agents have been used in the therapy of PCOS. The last few decades of research have recognized the central role of insulin in the pathogenesis.
Insulin sensitizing agents increase the tissue sensitivity to insulin action in vivo and enhance insulin activity in PCOS women. Metformin, an oral biguanide is commonly being used in clinical practice. It was the first insulin sensitising drug to be used in PCOS to investigate the role of insulin resistance in the pathogenesis of the syndrome. But, the action of metformin is limited due to low levels of inositol in PCOS. This problem leads the researchers to study in depth about the metabolism of glucose and the role of Phosphoinositol-3 kinase (PI 3 kinase). This brings about altered insulin signalling causing hyperinsulinaemia and insulin resistance.
Isoform of inositol belongs to the vitamin B complex. Myo-inositol, which is optically inactive, is the only form of the nine cyclohexanehexols with known biological importance. Free myo-inositol is produced in all eukaryotic cells and is present in all animal tissues. It accelerates the dephosphorylation of glycogen synthase and pyruvate dehydrogenase, both rate-limiting enzymes of nonoxidative and oxidative glucose disposal. Supplying D-chiro inositol or myo-inositol can accelerate glucose disposal and sensitize insulin action. Although Dchiro-inositol was the predominant form studied initially in PCOS, the focus of recent studies has been on myoinositol which is a precursor to D-chiro-inositol.
Various studies have been done on metformin, Dchiroinositol and myoinositol but there are very limited studies comparing the efficacy of these drugs in treatment of PCOS. In this study, we have compared the metabolic and hormonal effects of myoinositol and metformin in women with polycystic ovary syndrome.
Aim
To compare the metabolic and hormonal effects in patients receiving myoinositol to those receiving metformin. 
METHODS
The study was carried out at Jawaharlal 3. Polycystic ovaries (by ultrasound): Presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter and/or increased ovarian volume (>10 mL; calculated using the formula 0.5 x length x width x thickness). Even ovary fitting this definition was enough to define PCOS.
Inclusion criteria
All the females of age group 15-40 years attending OPD of Obstetrics and Gynaecology at AVBRH fulfilling the Rotterdam criteria.
Exclusion criteria
-Patients already on other drug treatment for PCOS(like oral contraceptive pills) -Deranged kidney or liver function tests -Thyroid disorders -Known hypersensitivity to myoinositol
Treatment modality
Approval was obtained from the ethical committee of the hospital. Patients were randomly allocated to treatment with either myoinositol (50 in myoinositol group) or metformin (50 in metformin group), by means of a computer generated number table, and by using sealed opaque envelopes, numbered and used consecutively. Prior to enrolment, a written informed consent was obtained from the patient. Women who met the inclusion criteria were subjected to treatment according to the randomisation number. The randomisation list was kept concealed until the study was complete. Baseline levels of the study variables were recorded. Participants of myoinositol group received myoinositol 1 gm twice daily and, of metformin group received 500 mg metformin tablet twice daily. The patients were called for follow up after 6 months of drug therapy and then all the baseline measurements were repeated. The anthropometric, biochemical and ultrasonography findings after 6 months of treatment were compared with the baselines findings in each study group. Infertility patients who conceived after treatment was noted. The side effects experienced in each study group was also noted down. Finally the efficacy of the two drugs, myoinositol and metformin, in improving the metabolic and hormonal parameters in the patients, was compared.
Statistical analysis
The data was analyzed using SPSS version 17 software. The statistical significance was tested at 5% level of significance. For continuous variables students t-test was used. Descriptive statistics were analysed for the data that were quantitative and expressed as mean & Standard Deviation (SD).
Unpaired t-test was used to compare the effect of myoinositol and metformin on the biochemical parameters.
RESULTS
Present study was carried out on 100 patients with PCOS. We used history, clinical examination and investigations as per Rotterdam Consensus-2003 criteria for defining PCOS. In the study group, total 47% patients had regular menstrual cycle and 53% had irregular cycle. Out of 53 patients, 15 patients had oligomennorrhoea and 28 presented with secondary amenorrhoea (Table 1) .
Overall, after six months of treatment, 20 (37.73%) achieved regular cycles, 28.57% with myoinositol and 48% after metformin treatment ( Table 2) . The reduction in the mean modified Ferriman Gallwey score (mFG) of hirsutism and acne was statistically significant in both the groups, but on comparing the two groups, the reduction was not significant. The mean fasting insulin decrease in myoinositol was from 16.51 ± 13.94 to 14.58 ± 9.79, which was statistically significant but in metformin group the reduction was not significant.
Homeostatic model assessment (HOMA) index, an index of insulin resistance. Decreased from mean of 4.21 ± 3.634 with P value of 0.001 in myoinositol group but the decrease was not significant in the metformin group. On comparing the two groups, the decrease in HOMA was significant with P value of 0.004 (Table 3) .
Seventy percent patients were married in study group. Out of those seventy married patients, 56.33% had presented with infertility (Table 4 ).
Out of 19 infertility patients in the myoinositol group, 36.84% conceived and out of 21 patients in metformin group, 33.33%. The results in the two groups were comparable but it was not significant statistically.
Total 36 out of 50 patients experienced the side effects of treatment with metformin. 2% patient had lactic acidosis, 38% generalized weakness, 32% had nausea and 28% did not have any side effects where as 84 % patients in the myoinositol group did not experience any side effect but 14% had menorrhagia and 2% had nausea. In the myoinositol group only 16% patients experienced side effect in contrast to 72% in the metformin group with a P value of <0.0001 which was statistically significant (Figure 1 ). 
DISCUSSION
Vincenzo et al. 4 compared the effect of metformin and myoinositol. Metformin group and myoinositol both showed significant improvement in regularisation of menses and reduction in FG score and BMI, insulin glucose and HOMA, testosterone, LH. But the study failed to establish superiority of one drug over the other.
Similarly Zacche 5 also found significant decrease in acne after treatment with myoinositol.
Cheang et al. 6 performed a study in which, after a mean follow-up of 36.1 months with metformin treatment, improvements were observed for BMI (decrease of -1.09 ± 3.48 kg/m 2 , P = 0.0117). In the present study BMI after treatment decreased from 23.97 ± 3.51 to 23.23 ± 2.65. WHR did not decrease significantly in myoinositol group (Table 3) . This was in contrast to study by Constantino et al. 7 Artini et al. 8 found that, in consideration of baseline fasting insulin levels, myo-inositol treatment induced similar changes in both groups but only patients in myoinositol group demonstrated significant reduction in fasting insulin levels (20.3 ± 1.8 to 12.9 ± 1.8 µU/mL, P <0.00001).
HOMA index, which is a measurement of insulin resistance decreased in myoinositol group significantly but not in metformin group. On comparison between the two group myoinositol had significantly better action in improving the insulin resistance (Table 3) . Zacche 5 also found that basal insulin levels and HOMA index significantly decreased after myoinositol treatment.
Artini et al. 8 found that myo-inositol treatment showed significantly lower Testosterone (2.3 nmol/liter vs. 3.4 nmol/liter; 95% CI = 0.07 and 2.1, respectively; P >0.04), similarly to our study. Zacche 5 also showed decrease in testosterone and LH levels after treatment with myoinositol.
No side effects or adverse events were observed in any of the study participants 7 in contrast, side effects were seen in 14% patients in our study (Figure 1 ) but these side effects were significantly very less than metformin (Figure 1 ) in which total of 72% patients had side effects (Figure 1 ). Artini et al. 8 also found no side effects or adverse events in any of the study participants receiving myoinositol.
The ovarian volume and Antral Follicle Count (AFC) reduced significantly in both metformin and myoinositol group (Table 3) . Another study 9 showed a significant reduction in mean ovarian volume (11.70 ± 4.31 ml vs. 8.27 ± 3.71 ml P = 0.001) after three months of treatment with metformin. 
CONCLUSION
Aim of our study was to compare the metabolic and hormonal effects of a chronic treatment with myoinositol versus metformin in PCOS patients. Using a comprehensive, detailed endocrinological and clinical assessment, we have shown that myoinositol and metformin, both the drugs resulted in significant weight loss, regularisation of menses and improvement in endocrinological parameters. In women with the PCOS, insulin resistance is related to a deficiency in myoinositol containing mediator of insulin action and the administration of the myo-inositol improves insulin sensitivity to conclude, metformin is effective in reducing the metabolic and hormonal parameters and also improves fertility but myoinositol not only improves all the above parameters but also decreases insulin resistance.
Myoinositol also has better patient compliance and well tolerated than metformin. These beneficial effects of inositol support a future therapeutic role in women with PCOS. Inositol deficiency is the basic pathophysiology for PCOS, hence inositol supplementation is essential in the management of PCOS to improve insulin sensitivity.
PCOS is not only a health hazard but also an economic burden. Based on the above observations it can be said that, since the clinical features of PCOS are heterogeneous, they have to be investigated accordingly, for selection of appropriate treatment modality. Early identification of high risk cases and timely therapeutic intervention can halt this on-going process and prevent long term complications.
